Testosterone-blocking therapy for male breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study tests an oral treatment (called “ET”) to treat hormone-receptor–positive, HER2-negative invasive breast cancer in men. It may help shrink or control cancer without using standard cancer treatments first.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 18 or older with invasive breast cancer
- Your cancer is hormone-receptor positive (ER or PR) and HER2 negative
- You have not had surgery to fully remove the main breast tumor and underarm (axillary) lymph nodes
- Your cancer is Stage I, II, or III (not Stage 4), and a doctor confirms the stage
- You must be able to swallow pills and agree to consent and a planned breast biopsy after an initial “window” period
- Your blood counts and organ tests are within the study limits (enough white cells, hemoglobin, platelets; acceptable kidney, liver, and bilirubin levels)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This trial tests whether adding hormone therapy (ADT) to stereotactic body radiation therapy (SBRT) works better than SBRT alone for men with a specific type of prostate cancer called 'unfavorable intermediate risk.' The goal is to see if the combination helps control the cancer better.
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
This study tests whether tamoxifen (a hormone-blocking medication) can help men's testosterone levels recover after they finish androgen deprivation therapy (ADT)—a common prostate cancer treatment that lowers testosterone. The goal is to see if tamoxifen can safely speed up testosterone recovery and improve quality of life.
Hear when a new Hormone-receptor-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.